Immunic (IMUX)
(Delayed Data from NSDQ)
$1.22 USD
-0.01 (-0.81%)
Updated May 30, 2024 04:00 PM ET
After-Market: $1.23 +0.01 (0.82%) 5:42 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Immunic, Inc. [IMUX]
Reports for Purchase
Showing records 141 - 160 ( 213 total )
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Safety Cleared in Rapidly Enrolling COVID Trial, Efficacy Data by YE2020
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Register For Week-1 of Our Management Talk Series With IVA, RAPT, KALV - AGTC
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Next Week We''ll Kick Off Our Management Talk Series
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Additional EMPhASIS Data Analyses Reinforce IMU-838 Profile; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Significant Market Opportunity for IMU-838 in RRMS. Reiterate Buy, $64 PT
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-838?s Best-in-Class Profile Continues to Shine at ACTRIMS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-838 Could Become a Very Strong Contender in MS.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Upcoming Webinars to Discuss Near-Term Catalysts with Our Covered Companies
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
We are updating coverage of our Healthcare sector to better allocate our research resources in
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Patient Dosing Begins in IMU-856 Phase 1; Next, Additional RRMS Data at ACTRIMS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-856 Clinical Trial Initiated; Financing Complete; Modulating PT to $56
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
First Healthy Volunteer Dosed with IMU-856, A Novel Drug for GI Diseases
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z